CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets

por Kohlmeyer, Jordan L, Gordon, David J, Tanas, Munir R, Monga, Varun, Dodd, Rebecca D, Quelle, Dawn E
Publicado 2020

RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner

por Kohlmeyer, Jordan L., Kaemmer, Courtney A., Umesalma, Shaikamjad, Gourronc, Francoise A., Klingelhutz, Aloysius J., Quelle, Dawn E.
Publicado 2021

Combination therapies for MPNSTs targeting RABL6A-RB1 signaling

por Kohlmeyer, Jordan L., Gordon, David J., Tanas, Munir R., Dodd, Rebecca D., Monga, Varun, Darbro, Benjamin W., Quelle, Dawn E.
Publicado 2021

Utility of CD138/syndecan-1 immunohistochemistry for localization of plasmacytes is tissue-dependent in B6 mice

por Meyerholz, David K., Leidinger, Mariah R., Goeken, J. Adam, Businga, Thomas R., Akers, Allison, Vizuett, Sebastian, Kaemmer, Courtney A., Kohlmeyer, Jordan L., Dodd, Rebecca D., Quelle, Dawn E.
Publicado 2022

Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas

por Desai, Chandni, Thomason, Jon, Kohlmeyer, Jordan L., Reisetter, Anna C., Ahirwar, Parmanand, Jahanseir, Khadijeh, Leidinger, Mariah, Ofori-Amanfo, Georgina, Fritchie, Karen, Velu, Sadanandan E., Breheny, Patrick, Quelle, Dawn E., Tanas, Munir R.
Publicado 2021

Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo

por Kohlmeyer, Jordan L, Kaemmer, Courtney A, Lingo, Joshua J, Voigt, Ellen, Leidinger, Mariah R, McGivney, Gavin R, Scherer, Amanda, Koppenhafer, Stacia L, Gordon, David J, Breheny, Patrick, Meyerholz, David K, Tanas, Munir R, Dodd, Rebecca D, Quelle, Dawn E
Publicado 2022